Open AccessB06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
Author(s) -
Mateos M,
Hari P,
Bahlis N,
Chari A,
Donk NWCJ,
Dholaria B,
Garfall AL,
Goldschmidt H,
Kortüm KM,
Krishnan A,
Martin T,
Morillo D,
Oriol A,
Reece D,
Rodriguez C,
RodríguezOtero P,
SanMiguel JF,
Usmani SZ,
Verona R,
Lin SXW,
Prior TJ,
Wade M,
Weiss B,
Goldberg JD,
Askari E
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000829564.55849.0d
Subject(s) - daratumumab , medicine , cd38 , oncology , adverse effect , multiple myeloma , proteasome inhibitor , bortezomib , stem cell , cd34 , biology , genetics